Ask a Reporter: What You Should Know About the Coronavirus Vaccine

A quick interview with the Blog’s resident vaccine journalist, Emily Mullin

Alexandra Sifferlin
Medium Coronavirus Blog

--

Credit: Maciej Frolow / Getty Images

There’s been a lot of recent vaccine news. After all, there are over 100 experimental vaccines in development for Covid-19. Emily Mullin is a staff writer at OneZero, where she covers biotech, and also makes time to report on the latest vaccine news for Medium’s Coronavirus Blog. After Oxford University published its latest data on its candidate vaccine this week, I chatted with Emily over Slack about covering the coronavirus vaccine race. Here’s our conversation:

Alexandra Sifferlin, blog editor: So Emily, new data on the Oxford trial was released yesterday, which we’ve been waiting for. Mainly because coverage so far seems to indicate it’s one of the furthest along. What’s your baseline impression of the data — is it really promising? Can I feel happy about this? 🙏

Emily Mullin, biotech reporter: I would say — no, not yet. So far, it doesn’t look significantly better than the data we’ve seen from other front-runners, like Moderna and Pfizer. But it’s also not any worse. We have to keep in mind that these are small, early-stage trials, and so far we’ve only seen a glimpse of data from a handful of these trials. We don’t have the full picture yet.

--

--

Alexandra Sifferlin
Medium Coronavirus Blog

Health and science journalist. Former editor of Medium’s Covid-19 Blog and deputy editor at Elemental. TIME Magazine writer before that